Complementary Therapies

High-dose intravenous Vitamin C (25–100 g) achieves plasma concentrations 100–500x higher than oral supplementation — concentrations shown to selectively kill cancer cells via hydrogen peroxide generation in tumour microenvironment while leaving normal cells unharmed. Multiple phase I/II clinical trials confirm safety and show tumour reduction in pancreatic, ovarian, and glioblastoma cancers. Used alongside conventional chemotherapy, IV-C has shown synergy and reduced treatment toxicity.

Methylene Blue (MB) is one of the oldest synthetic drugs (approved 1890s) now being re-discovered as a powerful mitochondrial electron carrier. At low doses (0.5–4 mg/kg), MB enhances mitochondrial respiration, generates reactive oxygen species selectively in cancer cells, and crosses the blood-brain barrier — making it uniquely relevant for brain tumours. It also has potent antimicrobial, antiviral, and neuroprotective properties.

IV Hydrogen Peroxide therapy involves very slow administration of highly diluted H₂O₂ (0.03–0.1%) directly into the bloodstream. Proponents claim it floods tissues with oxygen, selectively kills anaerobic organisms and cancer cells (which are known to be sensitive to oxidative stress), and stimulates immune function. This therapy has a long history in alternative medicine but lacks modern RCT evidence.

Medical ozone (O₃) is generated by passing pure oxygen through a calibrated ozone generator. The most studied cancer-relevant protocol is Major Autohemotherapy (MAH) — drawing 100–200 ml of blood, mixing with ozone, and reinfusing it. Ozone oxidises lipids in blood, generating ozonides (lipid peroxides) that act as secondary messengers, stimulate immune function, improve tissue oxygenation, and exert selective cytotoxicity against cancer cells. Used extensively in Germany, Italy, Russia, and Cuba as integrative oncology adjunct.

HBOT involves breathing 100% pure oxygen inside a pressurised chamber (1.5–3 atmospheres absolute), delivering oxygen to tissues at 10–15x normal atmospheric levels. Originally developed for decompression sickness, HBOT has extensive evidence for reducing radiation-induced tissue damage (osteoradionecrosis, soft tissue radiation injury) in cancer patients. Emerging evidence suggests HBOT sensitises hypoxic tumour cores to radiation/chemotherapy and may directly inhibit tumour growth.

Infrared sauna uses infrared radiation (near, mid, far) to heat the body from inside rather than heating the air. Core body temperature rises to 38.5–40°C, mimicking a therapeutic fever. Cancer cells have reduced heat shock protein expression and are more vulnerable to hyperthermia than normal cells. Regular sauna use is associated with 40–65% lower cancer mortality in Finnish population studies. Far-infrared sauna also powerfully eliminates toxins through sweat — including heavy metals, pesticides, and cancer-promoting environmental chemicals.

Low-Dose Naltrexone (1.5–4.5 mg at bedtime, vs. 50 mg addiction dose) transiently blocks opioid receptors for 4–6 hours, causing a rebound upregulation of endogenous opioids (endorphins) and opioid growth factor (OGF). OGF-OGF receptor signalling is a critical regulator of cell proliferation — LDN restores this to inhibit cancer cell growth. Used extensively in integrative oncology for haematological cancers, pancreatic cancer, and autoimmune conditions.

DCA (sodium dichloroacetate) is an industrial chemical that inhibits pyruvate dehydrogenase kinase (PDK), forcing cancer cells to shift from anaerobic glycolysis (the Warburg effect) back to mitochondrial oxidative phosphorylation. This reactivates apoptosis in cancer cells that use mitochondrial suppression to evade cell death. University of Alberta research (2007) sparked enormous interest, with subsequent case reports and small trials showing tumour regression in glioblastoma and other cancers.

Cold therapy encompasses cold water immersion (CWI at 10–15°C), whole-body cryotherapy chambers (−110 to −160°C for 2–3 min), and ice baths. In cancer care, cold exposure activates brown adipose tissue (BAT), which consumes glucose — depriving tumours. Wim Hof breathing protocol combined with cold reduces pro-inflammatory cytokines and stimulates norepinephrine (300% increase), which directly inhibits cancer cell proliferation. Cold therapy also dramatically reduces chemotherapy-induced peripheral neuropathy.

Photobiomodulation (PBM) uses red (630–700 nm) and near-infrared (800–900 nm) light to stimulate mitochondrial cytochrome c oxidase, increasing ATP production in normal cells. In oncology, PBM is clinically validated for reducing oral mucositis (mouth sores) from chemotherapy/radiation — one of the most painful and treatment-limiting side effects. Additionally, at specific wavelengths combined with photosensitisers (like Methylene Blue), PBM becomes photodynamic therapy (PDT) which directly kills cancer cells.

The Ketogenic Diet (KD) as cancer therapy exploits the Warburg effect — cancer cells' near-total dependence on glucose for energy. By restricting carbohydrates to <20–50 g/day, blood glucose and insulin drop dramatically, starving glucose-dependent tumours. Normal cells adapt to use ketones (from fat breakdown) as fuel; most cancer cells cannot. Pioneered by Dr Thomas Seyfried at Boston College, the metabolic theory of cancer suggests KD may be the most evidence-based dietary anti-cancer intervention. Multiple clinical trials are ongoing.

Coffee enemas are a core component of the Gerson Therapy — used 2–5 times daily in intensive cancer protocols. Organic coffee enemas stimulate the portal vein and the liver's glutathione S-transferase enzyme activity by 700%, dramatically enhancing the liver's capacity to detoxify tumour necrosis products, chemotherapy metabolites, and cancer-generated toxins. Palmitates in coffee cross the gut wall to directly stimulate liver detoxification pathways.

Therapeutic fasting starves cancer cells by depleting glucose and growth factors (IGF-1, insulin), while simultaneously protecting normal cells through cellular stress resistance. Dr Valter Longo's research shows that 48–72 hour fasting before chemotherapy protects normal cells (differential stress resistance/sensitisation — DSRS) while sensitising cancer cells to treatment. Intermittent fasting (16:8) and the Fasting Mimicking Diet (FMD) are more sustainable approaches with documented anti-cancer effects.

Sodium bicarbonate therapy is based on Dr Mark Pagel and Dr Tulio Simoncini's work showing that tumour microenvironments are highly acidic (pH 6.5–6.8) due to lactic acid production (Warburg effect). This acidity promotes invasion, metastasis, and drug resistance. Oral/IV bicarbonate raises tumour pH, reducing invasiveness. Clinical trials (MRI-guided) show sodium bicarbonate improves chemotherapy drug penetration into acidic tumours. Tumour pH monitoring via MRI spectroscopy is now possible.

Mistletoe (Viscum album) lectins (ML-I, ML-II, ML-III) are among the most studied natural anti-cancer compounds with over 100 clinical studies. Lectins induce apoptosis in cancer cells and stimulate NK cells, T-lymphocytes, and macrophages. Subcutaneous Iscador (standardised mistletoe extract) is standard of care integrative adjunct in European oncology (especially Germany), shown to improve quality of life, reduce chemotherapy side effects, and in some studies extend survival. IV mistletoe is now in FDA-approved clinical trials in the USA.

Molecular hydrogen (H₂) gas is the smallest and most penetrant antioxidant known — crossing all cell membranes including the blood-brain barrier. Unlike conventional antioxidants, H₂ selectively neutralises only the most cytotoxic free radicals (hydroxyl radical •OH and peroxynitrite ONOO⁻) without scavenging the 'beneficial' ROS used by immune cells. In cancer, H₂ reduces chemotherapy/radiation side effects, supports quality of life, and shows direct anti-cancer activity in several cancer cell lines.

Earthing (grounding) involves direct skin contact with the Earth's surface — barefoot walking on soil/grass, or using conductive grounding mats/sheets connected to the Earth. The Earth's surface maintains a negative electrical charge; electrons flow into the body on contact, acting as antioxidants. Peer-reviewed studies show grounding reduces cortisol, CRP (inflammation marker), improves sleep, reduces pain, and normalises circadian rhythm disruption — all highly relevant to cancer patients.

DMSO is a potent solvent and carrier molecule that penetrates all biological membranes including cell walls, skin, and the blood-brain barrier. In cancer therapy it is used primarily as a carrier to enhance transdermal or IV drug/supplement delivery. DMSO itself shows direct anti-tumour activity (differentiates cancer cells back to normal phenotype in some models) and as a carrier, dramatically increases the penetration of anti-cancer agents into tumours.

Dr William Coley (1890s) first observed that cancer patients who developed erysipelas (bacterial) infections sometimes experienced complete tumour remissions. He developed a mixed bacterial vaccine (Coley's Toxins — Streptococcus pyogenes + Serratia marcescens) that induced therapeutic fever (40–41°C), activating massive anti-tumour immune responses. Considered the historical predecessor of modern immunotherapy. Still used at select clinics, with documented complete remissions in sarcomas, lymphomas, and solid tumours.

IPT uses insulin to exploit cancer cells' overexpression of insulin receptors (IR) and IGF-1 receptors. A bolus of insulin drives blood glucose to 40–50 mg/dL (hypoglycaemic window), causing cancer cells to upregulate membrane receptors and open glucose transport channels — at this moment, low-dose chemotherapy (10–15% of standard dose) is administered IV. The theory: cancer cells in a nutrient-deprived, high-receptor state absorb dramatically more drug than normal cells.

Whole-body hyperthermia elevates core body temperature to 39–42°C using infrared cabins, water blankets, or radiant heat devices — mimicking but controlling a therapeutic fever. Cancer cells are more sensitive to heat than normal cells due to their abnormal vasculature (limited heat dissipation), reduced heat shock protein production, and altered metabolism. WBH is used in European oncology clinics (especially Germany) combined with chemotherapy to increase drug penetration and enhance immune response.

Intermittent Fasting (IF) involves cycling between defined eating and fasting windows daily. The most studied pattern is 16:8 — 16 hours fasting, 8 hours eating. A landmark study in breast cancer survivors (WHEL study) found that a 13-hour overnight fast reduced recurrence risk by 36%. IF lowers insulin, IGF-1, and inflammatory markers — all known cancer promoters — while activating autophagy (cellular clean-up) and shifting metabolism away from glycolysis towards fat oxidation.

Prolonged fasting of 48–72 hours before and after chemotherapy is the most clinically studied fasting protocol in oncology, pioneered by Dr. Valter Longo at USC. The mechanism — called Differential Stress Resistance (DSR) — exploits a fundamental difference between cancer cells and normal cells: normal cells downregulate growth and enter a protective mode during fasting, while cancer cells (locked into perpetual growth signalling via oncogene activation) cannot. This renders normal cells more resistant to chemo toxicity and cancer cells more sensitive. Clinical trials in breast, ovarian, and prostate cancer show reduced chemotherapy side effects and preliminary evidence of improved tumour response.

Water-only fasting involves complete abstinence from all calories while consuming plain water freely. Unlike intermittent fasting, water fasts are typically extended (24–120+ hours) and produce profound metabolic shifts: near-complete glycogen depletion by 24h, ketosis by 48h, and deep autophagy activation by 72h+. Used in integrative oncology for metabolic resetting, immune system renewal, and as preparation for chemotherapy. Valter Longo's research suggests that prolonged fasting (essentially water-only) promotes stem cell-based immune regeneration following chemotherapy — essentially 'rebooting' the immune system.

Dry fasting involves abstinence from both food AND water for a defined period. It is practised in some traditional and spiritual contexts (Ramadan, certain Ayurvedic protocols) and has recently attracted interest in alternative cancer communities. Proponents claim it produces deeper metabolic stress than water fasting and accelerates autophagy. The scientific evidence base is minimal compared to water fasting, and the risks — particularly dehydration, electrolyte disturbance, and kidney stress — are substantially higher. Dry fasting is NOT recommended during active cancer treatment. It is included here for completeness and to provide accurate risk information.

Acupuncture — the insertion of fine sterile needles at specific body points — has one of the strongest evidence bases of any complementary therapy in oncology. Multiple randomised controlled trials and systematic reviews confirm its effectiveness for chemotherapy-induced nausea and vomiting (CINV), cancer pain, fatigue, hot flashes (from hormone therapy), dry mouth (xerostomia from head/neck radiation), and peripheral neuropathy. It is now offered in major cancer centres including Memorial Sloan Kettering and MD Anderson Cancer Center.

Moxibustion involves burning dried mugwort (Artemisia vulgaris) near or on acupuncture points to generate gentle heat that penetrates deeply into tissue. In oncology, it is most studied for reverting breech presentation (unrelated to cancer), managing chemotherapy-induced leukopenia (low white blood cell count), fatigue, and digestive side effects. It is commonly used alongside acupuncture in Traditional Chinese Medicine cancer support. The heat stimulates immune function and improves microcirculation at treated points.

Cupping therapy uses suction cups applied to the skin to create negative pressure, mobilising blood and lymph flow. In oncology contexts it is used for muscle tension, cancer-related pain, respiratory congestion, and lymphoedema management. While clinical evidence in cancer is limited, its use for musculoskeletal pain and respiratory conditions (relevant for lung cancer patients) has moderate-quality evidence. It is a standard component of Traditional Chinese Medicine and is increasingly offered at integrative oncology centres.